Healthy Clinical Trial
Official title:
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [¹⁴C]-Tucatinib Following a Single Oral Dose in Healthy Male and Female Subjects
Verified date | November 2018 |
Source | Seattle Genetics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth. Patients will be monitored for 8-14 days after they take the dose of tucatinib.
Status | Completed |
Enrollment | 8 |
Est. completion date | January 30, 2018 |
Est. primary completion date | January 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, or lab evaluations - Body mass index (BMI) between 18 and 32 kg/m² - Weight between 50 and 100 kg - Females must be of non-childbearing potential - Males must agree to use contraception Exclusion Criteria: - History of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder - Any condition affecting drug absorption - History of hypersensitivity or allergy to any drug compound, food, or other substance - History of alcoholism or drug/chemical abuse within 2 years - Use of prescription products within 28 days prior to check in - Use of tobacco- or nicotine-containing products within 3 months prior to check in |
Country | Name | City | State |
---|---|---|---|
United States | Covance Clinical Research Unit | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Cascadian Therapeutics Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the concentration-time curve (AUC) from time 0 to infinity (AUC[0-inf]) | PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | AUC from time 0 to last quantifiable concentration | PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | Maximum observed concentration | PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | Time of maximum observed concentration | PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | Apparent terminal elimination half-life | PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | Apparent total clearance | PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | Apparent volume of distribution | PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles | Up to 14 days | |
Primary | AUC[0-inf] plasma tucatinib/total radioactivity ratio | AUC[0-inf] of plasma tucatinib relative to AUC[0-inf] of plasma total radioactivity | Up to 14 days | |
Primary | AUC[0-inf] blood/plasma ratio | AUC[0-inf] of whole blood total radioactivity to AUC[0-inf] of plasma total radioactivity | Up to 14 days | |
Primary | Amount excreted in urine (Aeu) | PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections | Up to 14 days | |
Primary | Cumulative Aeu | PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections | Up to 14 days | |
Primary | Percentage excreted in urine (Feu) | PK outcome endpoint of tucatinib and total radioactivity derived from urine collections | Up to 14 days | |
Primary | Cumulative Feu | PK outcome endpoint of tucatinib and total radioactivity derived from urine collections | Up 14 days | |
Primary | Renal clearance | PK outcome endpoint of tucatinib derived from urine collections | Up to 14 days | |
Primary | Amount excreted in feces [Aef] | PK outcome endpoint of total radioactivity derived from feces collection | Up to 14 days | |
Primary | Cumulative Aef | PK outcome endpoint of total radioactivity derived from feces collection | Up to 14 days | |
Primary | Percentage excreted in feces [Fef] | PK outcome endpoint of total radioactivity derived from feces collection | Up to 14 days | |
Primary | Cumulative Fef | PK outcome endpoint of total radioactivity derived from feces collection | Up to 14 days | |
Secondary | Relative abundance of tucatinib and its metabolites eliminated in urine and feces | Up to 14 days | ||
Secondary | Relative abundance of tucatinib and its metabolites in plasma | Up to 14 days | ||
Secondary | Incidence of adverse events (AEs) | Up to 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |